Renaissance Capital logo

Alpha Teknova Priced, Nasdaq: TKNO

Provides reagents and other materials for biopharmaceutical R&D applications.

Industry: Health Care

Latest Trade: $1.73 0.00 (0.0%)

First Day Return: +56.3%

Return from IPO: -89.2%

Industry: Health Care

We are a leading provider of critical reagents that enable the discovery, research, development and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Our 3,000 active customers span the entire continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions. Our company is built around proprietary manufacturing processes that are highly adaptable and versatile. These proprietary processes enable us to manufacture and deliver high quality, custom, made-to-order products on a short turnaround time and at scale, across all stages of development, including commercialization. Due to our expertise in supply chain management, product creation, chemical formulation, and QC, developed over more than two decades, we are typically able to move a new custom product into production in less than one week from order receipt. This allows our customers to potentially receive their products in weeks as compared to months from alternative suppliers employing traditional production environments.
more less
IPO Data
IPO File Date 06/04/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.0
Deal Size ($mm) $96
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/24/2021
Offer Price $16.00
Price Range $14.00 - $16.00
Offer Shares (mm) 6.0
Deal Size ($mm) $96
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
TD Cowen
William Blair
more
Company Data
Headquarters Hollister, CA, United States
Founded 2000
Employees 194
Website www.teknova.com

Alpha Teknova (TKNO) Performance